YOLFT
Liquidia Technologies Inc

Liquidia Technologies Inc

LQDA · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

$65.72+0.41 (+0.64%)

Close Sep 15, 2026 · end-of-day

Market Stats

Previous Close$65.31
Open$65.31
Day Range$62.86 – $65.93
52-Week Range$21.35 – $93.61
Volume1.37M
Market Cap$6.59B
P/E (TTM)52.62
Forward P/E10.53
EPS$1.4
Dividend Yield0.00%
Beta0.54
50-Day Avg$75.5
200-Day Avg$54.07

Price History

Open in new tab
Loading price history…

About

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Company Details

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Roger A. Jeffs Ph.D.
Employees
216
Headquarters
419 Davis Drive, Morrisville, NC, United States, 27560, USA
Website
https://www.liquidia.com

Leadership

  • Dr. Roger A. Jeffs Ph.D.CEO & Director · b. 1962
  • Mr. Michael KasetaCOO & CFO · b. 1976
  • Mr. Russell SchundlerGeneral Counsel & Corporate Secretary · b. 1976
  • Mr. Scott MoomawChief Commercial Officer · b. 1971
  • Dr. Rajeev Saggar M.D.Chief Medical Officer · b. 1975
  • Ms. Dana BoyleChief Accounting Officer · b. 1985
  • Mr. Christian Perez FontSenior VP, Chief Compliance Officer & Associate General Counsel
  • Mr. Michael PostSenior Vice President of Marketing
  • Ms. Sarah Krepp SPHRChief Human Resources Officer · b. 1982
  • Mr. Jason AdairChief Business Officer · b. 1973

Financials

Income Statement

Line item2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Total Revenue$158.32M$14.00M$17.49M$15.94M$12.85M$739.63K$8.07M$2.71M$7.26M$13.22M
Cost of Revenue$13.24M$5.88M$2.89M$2.86M$3.02M$237.71K$807.19K$121.39K$319.76K$918.78K
Gross Profit$145.08M$8.12M$14.60M$13.08M$9.83M$501.92K$7.26M$2.59M$6.94M$12.30M
Operating Income$-51.38M$-121.29M$-73.38M$-38.77M$-33.80M$-59.09M$-46.82M$-34.87M$-28.03M$-15.86M
EBITDA$-43.22M$-115.71M$-70.05M$-35.03M$-28.20M$-55.79M$-43.42M$-32.60M$-15.21M$-15.20M
Net Income$-68.92M$-130.39M$-78.50M$-41.02M$-34.58M$-59.76M$-47.58M$-53.14M$-29.15M$-15.93M
R&D$39.28M$47.84M$43.24M$19.43M$20.52M$32.22M$40.49M$28.70M$24.75M$23.32M
Interest Expense$24.17M$12.49M$6.27M$2.34M$762.00K$858.00K$1.37M$18.99M$13.01M$85.86K

Balance Sheet

Line item2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Total Assets$327.93M$230.31M$118.33M$129.20M$93.73M$99.53M$68.84M$49.42M$14.84M$8.49M
Total Liabilities$283.19M$153.04M$71.04M$38.78M$28.46M$28.45M$33.89M$30.73M$48.54M$26.73M
Total Equity$44.75M$77.28M$47.29M$90.42M$65.27M$71.09M$34.95M$18.69M$-33.69M$-18.25M
Cash$190.68M$176.48M$83.68M$93.28M$57.49M$65.32M$55.80M$39.53M$3.42M$1.44M
Total Debt$197.93M$122.39M$49.54M$24.46M$16.08M$17.14M$24.42M$12.77M$23.49M$8.68M
Net Debt$7.25M$-54.09M$-34.14M$-68.82M$-41.41M$-48.17M$-31.38M$-26.76M$18.73M$7.24M

Cash Flow

Line item2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating Cash Flow$-35.69M$-93.42M$-41.56M$-28.59M$-34.03M$-54.14M$-48.28M$-31.83M$-24.29M$-13.95M
Investing Cash Flow$-6.34M$-8.44M$-11.29M$-587.00K$-107.00K$247.91K$-1.85M$-870.94K$-2.54M$-2.89M
Financing Cash Flow$59.73M$194.66M$43.25M$64.96M$26.32M$63.42M$66.39M$68.82M$28.81M$6.11M
Capital Expenditure$4.34M$4.95M$1.29M$592.00K$107.00K$752.09K$1.85M$870.94K$2.54M$2.89M
Free Cash Flow$-40.02M$-98.37M$-42.85M$-29.18M$-34.14M$-54.90M$-50.13M$-32.70M$-26.83M$-16.83M

Earnings

Report DateNov 2, 2026Aug 12, 2026May 11, 2026Mar 12, 2026Nov 3, 2025Aug 12, 2025May 8, 2025Mar 19, 2025Nov 13, 2024Aug 7, 2024May 13, 2024Mar 13, 2024Nov 7, 2023Aug 10, 2023May 4, 2023Mar 16, 2023Nov 8, 2022Aug 11, 2022May 12, 2022Mar 17, 2022Nov 3, 2021Aug 10, 2021May 13, 2021Mar 22, 2021Nov 6, 2020Aug 10, 2020May 11, 2020Mar 11, 2020Nov 13, 2019Aug 8, 2019May 2, 2019Feb 26, 2019Oct 31, 2018Aug 14, 2018Apr 11, 2018
EPS Estimate$0.89$0.70$0.41$0.19$-0.35$-0.39$-0.42$-0.38$-0.40$-0.33$-0.32$-0.23$-0.19$-0.16$-0.17$-0.15$-0.19$-0.22$-0.20$-0.11$-0.15$-0.16$-0.21$-0.36$-0.36$-0.48$-0.55$-0.59$-0.72$-0.72$-0.62$-0.61$-0.58$-3.41$0.00
EPS Actual-$-0.49$0.52$0.15$-0.04$-0.49$-0.45$-0.46$-0.39$-0.37$-0.54$-0.42$-0.24$-0.36$-0.15$-0.09$-0.14$-0.15$-0.28$-0.23$-0.14$-0.13$-0.21$-0.38$-0.40$-0.49$-0.52$-0.71$-0.72$-0.31$-0.87$-0.63$-0.62$-0.62$-1.85
Surprise--170.00%28.40%-21.96%88.57%-25.64%-7.14%-21.05%2.50%-12.12%-68.75%-82.61%-26.32%-125.00%11.76%40.00%26.32%31.82%-40.00%-109.09%6.67%18.75%0.00%-5.56%-11.11%-2.08%5.45%-20.34%0.00%56.94%-40.32%-3.28%-6.90%81.82%-
Timing-Pre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap
$6.59B
Enterprise Value
$5.94B
Trailing P/E
52.62
Forward P/E
10.53
Price / Sales
14.62
Price / Book
30.96
EPS
$1.4
Book Value
$2.19
Revenue (TTM)
$450.91M
Gross Profit (TTM)
$417.28M
EBITDA
$169.77M
Profit Margin
30.74%
Operating Margin
49.81%
Return on Equity
131.82%
Return on Assets
27.04%
Shares Outstanding
89.51M
Shares Float
63.51M
Beta
0.54
Dividend Yield
0.00%
Dividend Rate
$0
Payout Ratio
0.00%

Analyst Ratings

Sell
Based on 10 analystsTarget $107.75
  • Strong Buy
    6
  • Buy
    3
  • Strong Sell
    1

Ownership Breakdown

Institutions
81.83%
Insiders
11.32%
Retail / Other
6.85%

Top Institutional Holders

  • Farallon Capital Management, L.L.C.
    8.66M9.67%
  • Caligan Partners LP
    8.12M9.07%
  • BlackRock Inc
    5.49M6.13%
  • Findell Capital Management LLC
    3.50M3.91%
  • Vanguard Capital Management, LLC
    2.93M3.27%
  • Opaleye Management Inc
    2.45M2.73%
  • Bank of America Corp
    2.29M2.56%
  • Geode Capital Management, LLC
    1.93M2.16%
  • State Street Corp
    1.88M2.10%
  • Caprock Group Inc
    1.41M1.57%
  • MPM Oncology Impact Management LP
    1.39M1.55%
  • D. E. Shaw & Co LP
    1.27M1.42%
  • Susquehanna International Group, LLP
    1.00M1.12%
  • T. Rowe Price Associates, Inc.
    953.15K1.06%
  • Federated Hermes Inc
    816.19K0.91%
  • The Goldman Sachs Group Inc
    811.99K0.91%
  • Jane Street Group LLC
    795.88K0.89%

Top Fund Holders

  • iShares Core S&P Small-Cap ETF
    4.28M4.78%
  • Vanguard MStar Total Stk Mkt Idx Invest
    2.26M2.53%
  • iShares Russell 2000 ETF
    1.80M2.01%